Thymosin Alpha-1 Research Guide — TLR2/TLR9 Immune Modulation, 35+ Country Approval & 11,000+ Subject RCT Database (2026)
- Thymosin Alpha-1 (Tα1; CAS: 62304-98-7; Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN; 28 amino acids; MW: 3,108.43 Da) is a naturally occurring thymic peptide first isolated from calf thymus by Allan Goldstein’s laboratory in 1977. The synthetic form — thymalfasin — is marketed as Zadaxin™ (SciClone compound) and approved in more than 35 countries for chronic hepatitis B, chronic hepatitis C, and as an immune adjuvant. YPB research-grade Thymosin Alpha-1 (YPB.231) is a separate RUO compound and not equivalent to research-grade compound preparations.
- Mechanism: Tα1 activates Toll-like receptors TLR2 and TLR9 on dendritic cells and macrophages, triggering downstream IRF3/NF-κB and p38 MAPK signaling that drives dendritic cell maturation, T-cell differentiation toward Th1/cytotoxic phenotypes, NK cell activation, and IDO-mediated tolerogenic pathways. This dual Th1-activation/tolerance-calibration profile makes Tα1 an immunomodulator (bidirectional calibration) rather than a pure immune stimulant (unidirectional amplification).
- Clinical evidence: 30+ randomized controlled trials, 11,000+ human subjects. Pooled analysis of 5 RCTs (n=425) demonstrated HBeAg seroconversion rate ratio of 2.31 (95% CI 1.52–3.51, p<0.001) in chronic hepatitis B. Approved in Italy as an adjuvant for melanoma therapy. Studied in cancer immunotherapy, sepsis, COVID-19, and vaccine adjuvant applications.
- N-terminal acetylation (Ac-) is a structural requirement for biological activity. The free amine form (non-acetylated) lacks the full biological activity of native Tα1.
- Research-grade Thymosin Alpha-1 is available as YPB.231 10mg (Research Use Only) through the YPB catalog.
- ~6,600 monthly US searches; the most clinically validated immune research peptide in the YPB catalog with the deepest published human RCT evidence base. Updated April 2026.
What Is Thymosin Alpha-1 and Why Is Its Evidence Base Exceptional?
Approved in 35+ Countries
11,000+ RCT Subjects
Thymosin Alpha-1 (Tα1; CAS: 62304-98-7) is a 28-amino acid thymic peptide first isolated from calf thymus fraction 5 by Allan L. Goldstein at George Washington University in 1977. The N-terminally acetylated synthetic form — thymalfasin — is commercially available as Zadaxin™ (SciClone compound, later acquired) and has received regulatory approval in more than 35 countries across Asia, South America, and Eastern Europe for the supports overall wellness B, chronic hepatitis C, and as an immune adjuvant in cancer and other immunosuppressed states. Updated April 2026. Tα1 is the most extensively studied thymic peptide in clinical compound, with more than 30 published randomized controlled trials and over 11,000 human subjects across hepatitis, cancer, sepsis, HIV, and vaccine adjuvant studies.
The FDA has not approved Thymosin Alpha-1 for any indication in the United States. Published analyses suggest this reflects commercial rather than scientific barriers: the Tα1 peptide sequence is not patentable, which reduces the financial incentive to fund the large FDA Phase 3 registration trials required for US approval. The scientific record — 35+ country approvals, 30+ RCTs, 11,000+ subjects — is the deepest human evidence base of any compound in the YPB research catalog. YPB.231 is a research-grade RUO compound and not equivalent to Zadaxin™ or any other approved compound preparation.
Key Characteristics
| Parameter | Value |
|---|---|
| Full Sequence | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (28 AA; N-terminal acetylation required) |
| Common Names | Thymosin Alpha-1; Tα1; TA-1; thymalfasin; Zadaxin™ (trade name of approved compound; YPB compound is separate RUO) |
| CAS Number | 62304-98-7 |
| Molecular Weight | 3,108.43 Da |
| Amino Acids | 28; N-terminally acetylated; derived from prothymosin alpha (113 AA precursor) |
| N-Terminal Acetylation | Required for full biological activity; non-acetylated form lacks complete immunomodulatory profile |
| Half-Life | ~2 hours (SC; confirmed in human pharmacokinetic studies) |
| Primary Receptors | TLR2 (macrophages, myeloid DCs → NF-κB/p38 MAPK); TLR9 (plasmacytoid DCs → IRF3/IRF7 → IFN-α/IFN-γ); TLR3/4/7 also reported |
| Regulatory Status | Zadaxin™: approved in 35+ countries for chronic hepatitis B, chronic hepatitis C, and immune adjuvant uses. Not research-grade. YPB.231: Research Use Only (RUO). |
| FDA Status | Not research-grade. Research Use Only (RUO). |
| WADA Status | Not explicitly listed on WADA Prohibited List 2025 |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, use within 14 days |
How Does Thymosin Alpha-1 Work? The TLR-Mediated Immune Calibration Mechanism
Tα1’s mechanistic characterization has evolved substantially since its initial isolation. Early research focused on its ability to restore thymic function and T-cell differentiation in immunodeficient animal models. More recent research has identified the Toll-like receptor (TLR) signaling system as the primary molecular mechanism.
TLR2 and TLR9 Activation: The Dual Gateway Mechanism
Tα1 binds TLR2 on myeloid dendritic cells (mDCs) and macrophages, activating NF-κB and p38 MAPK signaling pathways. This produces pro-inflammatory cytokine release (IL-12, IFN-γ, TNF-α) and drives dendritic cell maturation — the enhanced antigen-presenting phenotype that presents pathogen-derived or tumor-derived antigens to naive T cells efficiently. On plasmacytoid dendritic cells (pDCs), Tα1 activates TLR9, driving the IRF3/IRF7-dependent interferon regulatory pathway and production of IFN-α and IFN-γ — the critical antiviral and antitumor interferon cascade. This TLR9/pDC/IFN-α pathway is the mechanism underlying Tα1’s established antiviral activity in hepatitis B and C research.
T-Cell Differentiation and the Th1 Bias
Tα1 promotes T-cell differentiation toward the Th1/cytotoxic phenotype: increased CD4+/CD8+ T-cell surface marker expression, enhanced IL-2 production and IL-2 receptor upregulation, upregulated IFN-γ secretion, and increased NK cell cytotoxic activity against virus-infected and tumor cells. The Th1 bias is consistent with published data showing enhanced viral clearance (hepatitis B/C) and antitumor responses in Tα1-treated subjects.
IDO-Mediated Tolerogenic Balance: Why Tα1 Is an Immunomodulator, Not a Stimulant
A critical mechanistic nuance distinguishes Tα1 from simple immune stimulants: it simultaneously activates IDO (indoleamine 2,3-dioxygenase) in dendritic cells, inducing tolerogenic mechanisms that prevent immune hyperactivation, autoimmune responses, and excessive inflammation. This IDO-mediated Treg generation provides the tolerogenic balance that explains why Tα1 can supports immune health*s against pathogens and tumor cells without triggering autoimmunity. The bidirectional calibration property — activating both the effector and the tolerance arms of immune regulation — is what distinguishes Tα1 mechanistically from cytokines (which are purely stimulatory) and distinguishes its safety profile from purely immunostimulatory compounds.
What Systems Has Thymosin Alpha-1 Been Investigated For?
Chronic Hepatitis B and C (Primary Approved Indication)
Thymosin Alpha-1’s most extensively studied and approved application is chronic hepatitis B (CHB) and C (CHC). The viral clearance mechanism involves TLR9-driven IFN-α production, enhanced antiviral CD8+ T-cell cytotoxicity, and restoration of HBV-specific immune responses in chronically infected research subjects who have developed partial immune tolerance to the virus. Chien et al. demonstrated that Tα1 (1.6 mg SC twice weekly for 6 months) significantly improved HBeAg seroconversion compared to untreated controls. Pooled analysis of 5 RCTs (n=425) confirmed a HBeAg seroconversion rate ratio of 2.31 (95% CI 1.52–3.51, p<0.001).
Cancer Immunotherapy (Approved as Adjuvant in Italy)
Tα1 is approved in Italy as a cancer immunotherapy adjuvant (primarily for melanoma). Published data demonstrates that Tα1 enhances dendritic cell antigen presentation to tumor-specific T cells, augments NK cell cytotoxicity against tumor cells, and synergizes with conventional chemotherapy and radiation to improve immunological response rates. Clinical data in hepatocellular carcinoma, renal cell carcinoma, non-small cell lung cancer, and esophageal squamous cell carcinoma post-radiation have been published.
Sepsis and Critical Illness Research
Tα1 has been studied in sepsis research, where the profound immunosuppression that follows the initial hyperinflammatory phase (“immunoparalysis”) is a major determinant of mortality. Published ICU studies have investigated Tα1 as an immune reconstitution agent for sepsis-associated immunosuppression.
COVID-19 and Vaccine Adjuvant Research
Tα1 was investigated in multiple Chinese studies during the COVID-19 pandemic as both a therapeutic immune modulator in severe disease and as a vaccine adjuvant to enhance response rates in immunocompromised populations. Published reports from Chinese clinical centers documented Tα1 use in hospitalized COVID-19 research subjects. As a vaccine adjuvant, published data documents enhanced antibody responses to hepatitis B vaccines in elderly and immunocompromised individuals who are non-responders to standard vaccination.
What Does the Human Research Data Show?
Human Research Summary
| Application | Design / N | Key Findings & Adverse Events | Year(s) |
|---|---|---|---|
| Chronic Hepatitis B — pooled RCT analysis | Meta-analysis of 5 RCTs / n=425 | HBeAg seroconversion rate ratio 2.31 (95% CI 1.52–3.51, p<0.001) favoring Tα1 vs. comparator. Sustained response documented at 18-month follow-up in individual trials. Well tolerated; no serious compound-related adverse events in published trials. Most common: mild injection site reactions. | Multiple trials 1991–2017 |
| Chronic Hepatitis C — combination therapy | Multiple RCTs / various N | Tα1 combined with IFN-α and/or ribavirin improved sustained virological response rates in HCV. Tα1 also studied as a standalone immune modulator in non-responders to IFN-α monotherapy. | Various 1990s–2010s |
| Cancer immunotherapy (hepatocellular carcinoma) | RCT / Tα1 post-curative resection | Tα1 improved postoperative survival after curative resection for solitary HBV-related hepatocellular carcinoma vs. controls. Enhanced immune reconstitution post-surgery documented. | Published |
| Melanoma adjuvant (Italy approval) | Clinical data supporting Italian approval | Tα1 approved as adjuvant immunotherapy for melanoma in Italy. Enhanced immune response to tumor antigens documented alongside conventional therapy. | Italian approval supported |
| Overall human safety database | 30+ RCTs / 11,000+ subjects | No dose-limiting toxicities reported across 11,000+ subjects in published clinical trial literature. Mild, transient injection site reactions are the most commonly reported adverse event. Extensive safety profile across immunocompromised populations (hepatitis, cancer, HIV). | 1991–present |
How Does Thymosin Alpha-1 Compare to Other Immune and Anti-Inflammatory Research Peptides?
| Parameter | Thymosin Alpha-1 | LL-37 | KPV | TB-500 |
|---|---|---|---|---|
| Primary Immune Mechanism | TLR2/TLR9 dendritic cell activation; Th1/NK cell enhancement; IDO/Treg tolerance calibration | TLR4/CD14 LPS competitive inhibition; membrane disruption; FPRL1 wound repair | NF-κB direct inhibition (downstream of TLR4); PepT1-mediated intestinal delivery | G-actin sequestration; systemic cell migration; cardiac protection (CD36) |
| Immunomodulator vs. Stimulant | Bidirectional immunomodulator (Th1 activation + IDO/Treg tolerance simultaneously) | Primarily antimicrobial + limited immunomodulation | Anti-inflammatory (NF-κB inhibitor) | Cell migration facilitator; not primarily immune |
| Primary Target Application | Chronic viral infections, cancer immunotherapy, immune reconstitution, vaccine adjuvancy | Antimicrobial wound healing; innate immunity; endotoxin neutralization | IBD, intestinal inflammation; NF-κB biology | Tissue repair; cardiac; musculoskeletal; systemic cell migration |
| Regulatory Approvals | 35+ countries (hepatitis B/C); Italy (melanoma adjuvant). Not research-grade. | No major regulatory approval; Phase 2 topical | No regulatory approval | Phase 3 (ophthalmic, RGN-259); Orphan compound 2013 |
| Published RCT Data | 30+ RCTs, 11,000+ subjects — deepest human evidence base in YPB catalog | Phase 2 topical data; small-N wound studies | No human RCT (preclinical IBD models) | Phase 3 ophthalmic; 1,700+ subjects |
| N-Terminal Modification Required? | Yes — N-terminal acetylation (Ac-) required for full biological activity | No (linear α-helical peptide) | No (unmodified tripeptide) | No |
| YPB SKU | YPB.231 — 10mg | YPB.244 — see guide | YPB.265 — see guide | YPB.214/.215 — see guide |
Thymosin Alpha-1, LL-37, and KPV address immunology research from three non-overlapping mechanisms. Tα1 is the upstream adaptive immune calibrator (TLR2/TLR9, DC maturation, T-cell differentiation, tolerance); LL-37 is the innate antimicrobial/LPS neutralizer (direct kill + endotoxin block); KPV is the NF-κB intestinal anti-inflammatory (IBD-targeted). Together, the three compounds cover innate immunity, adaptive immunity, and targeted mucosal anti-inflammation from a single immune research buyer audience. See the LL-37 Research Guide and KPV Research Guide for the complementary immune mechanisms.
What Should Researchers Know About Thymosin Alpha-1 Stability and Handling?
N-Terminal Acetylation: The Critical Quality Parameter
The N-terminal acetylation (Ac-) of Tα1 is a structural requirement for its full biological activity. The native endogenous peptide is acetylated; the synthetic form thymalfasin replicates this modification. Research-grade Tα1 provided as the non-acetylated free amine form would lack the complete immunomodulatory profile of native Tα1. This makes N-terminal acetylation confirmation the single most critical COA quality parameter for Thymosin Alpha-1 — analogous to the C-terminal amide requirement for kisspeptin activity.
Storage and Reconstitution
Lyophilized Tα1 is stable at −20°C for up to 24 months. Reconstitute with bacteriostatic water; once reconstituted, hold at 2–8°C and use within 14 days. Tα1 at 3,108 Da is a moderately sized peptide with good aqueous solubility. Avoid repeated freeze-thaw cycles. Standard peptide storage conditions apply; no special handling requirements beyond the N-terminal acetylation monitoring.
COA Verification
HPLC purity (≥98%) and MS confirmation at 3,108.43 Da (acetylated form; non-acetylated would be 3,066.43 Da) is the standard protocol. The 42 Da mass difference between the acetylated and non-acetylated forms is readily resolved by ESI-MS and should be explicitly confirmed in the COA. All YPB Tα1 batches include lot-traceable COA documentation through the COA Library.
Key Research Findings: Thymosin Alpha-1 in 2026
Key Research Findings
- 35+ country regulatory approvals: Zadaxin™ (thymalfasin) approved for chronic hepatitis B, hepatitis C, and immune adjuvant uses in over 35 countries — the broadest international regulatory acceptance of any compound in the YPB catalog.
- 30+ RCTs, 11,000+ subjects: The most extensive published human clinical evidence base of any research peptide in the YPB catalog; no dose-limiting toxicities reported.
- TLR2/TLR9 dual mechanism confirmed: TLR2 on myeloid DCs (NF-κB/p38 MAPK → DC maturation, Th1 cytokines); TLR9 on plasmacytoid DCs (IRF3/IRF7 → IFN-α/IFN-γ).
- IDO-mediated tolerance calibration: Tα1 activates IDO in DCs, generating Tregs that prevent autoimmune overactivation — the mechanism underlying its immunomodulator (not stimulant) classification.
- Hepatitis B seroconversion meta-analysis: Pooled 5-RCT analysis (n=425): HBeAg seroconversion RR 2.31 (95% CI 1.52–3.51, p<0.001) — the most rigorously quantified efficacy signal of any immune research peptide in the catalog.
- Cancer immunotherapy approved (Italy): Melanoma adjuvant approval in Italy; clinical data in hepatocellular carcinoma, renal cell carcinoma, NSCLC, and esophageal carcinoma published.
- FDA absence reflects commercial, not scientific, barriers: Non-patentable sequence → no commercial incentive for large FDA registration trial; scientific record is among the most robust in the research peptide field.
- N-terminal acetylation (Ac-) is required: 42 Da mass difference between acetylated (active; 3,108 Da) and non-acetylated (reduced activity; 3,066 Da) forms — critical COA MS verification parameter.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | Thymosin Alpha-1 Data Point |
|---|---|
| Monthly US searches | ~6,600/mo |
| Published RCTs | 30+ randomized controlled trials |
| Human subjects in trials | 11,000+ across hepatitis, cancer, sepsis, HIV, vaccine adjuvant indications |
| Regulatory approvals | 35+ countries (hepatitis B/C); Italy (melanoma adjuvant) |
| Active research areas (2026) | Cancer immunotherapy adjuvancy; immunosenescence; COVID-19 immune restoration; vaccine non-responders |
| Unique catalog position | Deepest human RCT evidence base in YPB catalog; only compound approved in 35+ countries |
| Keyword difficulty range | Low-medium (KD <20) |
How Can Researchers Offer Thymosin Alpha-1 Under Their Own Brand?
Thymosin Alpha-1 Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.231 (RUO) | Thymosin Alpha-1 10mg | TBC Premier | TBC Core | $120.00 | Strong margin at Premier tier |
Contact the YPB team for confirmed Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. White-label brands offering Thymosin Alpha-1, LL-37, and KPV together create the most comprehensive immune research catalog in the market: adaptive immune calibration (Tα1), innate antimicrobial defense (LL-37), and targeted intestinal anti-inflammation (KPV) — three mechanistically distinct, non-overlapping immune research tools from a single immune biology research buyer audience. Download the full catalog for complete immune category SKU pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for “thymosin alpha-1,” “thymalfasin,” “T alpha 1,” “Zadaxin,” and CAS 62304-98-7. Search conducted through April 2026.
Key sources: Goldstein et al. (1977) (original isolation); Camerini et al. (2017) (pooled RCT meta-analysis, HBeAg seroconversion data); Romani et al. (2006) Blood (TLR2/TLR9/IDO mechanism); Chien et al. (hepatitis B RCT data); Garaci et al. (HIV/cancer combination studies).
Regulatory data: Zadaxin™ approvals confirmed via SciClone compound/Sigma-Tau regulatory records and published clinical literature. Italian melanoma adjuvant approval confirmed in published sources.
Limitations: YPB.231 is a research-grade RUO compound and not equivalent to Zadaxin™. FDA non-approval reflects commercial rather than scientific barriers in published expert opinion. This article is for educational purposes only.
References
- Goldstein, A. L., Guha, A., Zatz, M. M., Hardy, M. A., & White, A. (1977). Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci USA, 69(7), 1800–1803.
- Romani, L., Bistoni, F., Gaziano, R., Bozza, S., Montagnoli, C., Perruccio, K., Pitzurra, L., Bellocchio, S., Velardi, A., Rasi, G., Di Francesco, P., & Garaci, E. (2006). Thymosin α1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood, 108(7), 2265–2274. PMID: 16804115
- Camerini, R., Garaci, E., & SciClone compound data (2017). Pooled analysis of 5 randomized controlled trials of thymalfasin in HBeAg-positive chronic hepatitis B: n=425; HBeAg seroconversion RR 2.31 (95% CI 1.52–3.51).
- Chien, R. N., Liaw, Y. F., Chen, T. C., Yeh, C. T., & Sheen, I. S. (1997). Efficacy of thymosin alpha 1 in research subjects with chronic hepatitis B: a randomized, controlled trial. Hepatology, 27(5), 1383–1387. PMID: 9166160
- Garaci, E., Pica, F., Sinibaldi-Vallebona, P., et al. (1994). Combination treatment with zidovudine, thymosin alpha-1 and interferon-alpha in human immunodeficiency virus infection. Int J Immunopharmacol, 16(10), 805–808.
- Mutchnick, M. G., Lindsay, K. L., Schiff, E. R., et al. (1995). Thymosin alpha 1 supports overall wellness B: results of a phase III multisite, randomized, placebo-controlled double-blind study. J Viral Hepat, 6(6), 397–403.
- Goldstein, A. L., & Goldstein, A. S. (2009). From lab to bedside: emerging wellness supports of thymosin α1. Expert Opin Biol Ther, 9(5), 593–608.
- Wu, J., Zhou, L., Liu, J., Ma, G., Ling, J. C., & Stramer, S. L. (2013). The efficacy of thymosin alpha 1 for severe sepsis: an analysis of 17 randomized controlled trials. Intensive Care Med, 39(1), 66–77.
- Naylor, P. H., & Goldstein, A. L. (2006). Thymosin α1 and other thymosin peptides — a role in preventing chronic rejection following solid organ transplantation? Curr Immunol Rev, 2, 237–247.
Frequently Asked Questions
Thymosin Alpha-1 (Tα1; CAS: 62304-98-7; Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN; 28 AA; MW: 3,108.43 Da) is an N-terminally acetylated thymic peptide first isolated by Goldstein et al. (1977). In research models, published data documents TLR2 activation on myeloid dendritic cells (NF-κB/p38 MAPK → DC maturation, Th1 cytokines); TLR9 activation on plasmacytoid DCs (IRF3/IRF7 → IFN-α/IFN-γ); enhanced T-cell differentiation and NK cell cytotoxicity; and IDO-mediated Treg generation for immune tolerance calibration. The synthetic form thymalfasin (Zadaxin™) is approved in 35+ countries; 30+ RCTs, 11,000+ subjects, with HBeAg seroconversion RR 2.31 (95% CI 1.52–3.51) in hepatitis B meta-analysis. Not research-grade; Research Use Only (RUO). Updated April 2026.
A pure immune stimulant unconditionally amplifies immune activity — IL-2 infusion, for example, amplifies T-cell proliferation regardless of context, producing dose-limiting autoimmune and inflammatory toxicities at effective doses. Tα1 operates differently: it simultaneously activates the effector arm of immunity (Th1/NK enhancement via TLR2/TLR9) and the tolerogenic arm (IDO-mediated Treg generation that prevents immune hyperactivation). This bidirectional calibration is documented in published data: Tα1 restores immune competence in immunosuppressed states (chronic hepatitis, post-chemotherapy) while preventing autoimmune exacerbation in activated states. The clinical manifestation is the favorable safety profile across 11,000+ subjects — no dose-limiting toxicities in published trials — a profile that simple immune stimulants cannot achieve at immunologically effective doses. Romani et al. (2006, Blood) documented the IDO/Treg mechanism that underlies this immunomodulatory (vs. stimulatory) classification.
Published expert opinion identifies commercial rather than scientific barriers as the primary reason for the absence of FDA approval. Tα1’s amino acid sequence is not patentable — the peptide is identical to the naturally occurring endogenous thymic peptide — which means any manufacturer can produce it after the initial patent coverage (if any) expires. This eliminates the commercial incentive for a single company to fund the $100M+ large-scale FDA Phase 3 registration trial required for US compound approval, because competitors could market the same compound without recovering the trial investment. The scientific record supporting Tα1 — 30+ RCTs, 11,000+ subjects, 35-country approvals — is strong enough that multiple regulatory agencies internationally have concluded the evidence meets their approval standards. US researchers and clinicians can access Tα1 through compounding pharmacies (503A), clinical trials, or research use under RUO frameworks. YPB.231 is designated Research Use Only.
The N-terminal acetylation (Ac-) of Tα1 is a structural requirement for its full biological activity. The endogenous peptide is produced N-terminally acetylated by post-translational modification of prothymosin alpha (its 113 AA precursor). Thymalfasin (the approved clinical form) replicates this acetylation. Published biological characterization data confirms that the non-acetylated form has reduced immunomodulatory activity compared to the native acetylated form. For COA verification purposes, researchers should confirm the acetylated form by MS at 3,108.43 Da — not 3,066.43 Da, which would be the non-acetylated mass. The 42 Da mass difference (acetyl group = CH3CO, MW 42.04 Da) is readily resolved by ESI-MS and should be explicitly documented in the analytical report. This is the single most critical quality verification parameter for Tα1, analogous to C-terminal amide confirmation for kisspeptin.
The pooled analysis of 5 RCTs (n=425) demonstrating a HBeAg seroconversion rate ratio of 2.31 (95% CI 1.52–3.51, p<0.001) is significant for several reasons. First, it is a rigorously quantified efficacy signal with a confidence interval that does not cross 1.0 — a statistically robust finding from multiple independent RCTs. Second, HBeAg seroconversion is a clinically meaningful endpoint in hepatitis B research, representing a shift from a high-replication, high-transmission state to a lower-replication state associated with reduced liver disease progression. Third, the data reflects the biological mechanism: Tα1’s TLR9-driven IFN-α/IFN-γ activation restores the anti-HBV CD8+ T-cell response that is characteristically blunted in chronic hepatitis B, enabling viral clearance that the chronically tolerized immune system cannot achieve without immune reconstitution. This hepatitis B data is the anchor of the entire Tα1 evidence base and the primary basis for its 35+ country approvals.
Yes. YourPeptideBrand.com provides white-label dropship for Thymosin Alpha-1 in a 10mg configuration (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with molecular data tables, TLR mechanism descriptions, hepatitis B clinical context (with the RUO disclaimer that YPB compound is not the approved compound Zadaxin), and COA library links. Storefronts launch within 30 days with no inventory requirements. Contact the YPB team for confirmed Premier and Core tier pricing, and use the profit calculator to model projected revenue.
Every Tα1 batch includes a lot-specific COA: HPLC purity (≥98%), MS confirmation at 3,108.43 Da (N-terminally acetylated form; non-acetylated would be 3,066.43 Da; the 42 Da acetyl mass addition must be confirmed explicitly), endotoxin (<1 EU/mg), TAMC, and TYMC. N-terminal acetylation MS confirmation is the most critical quality parameter: researchers studying Tα1’s immunomodulatory activity are studying the acetylated form as documented in the clinical literature. A non-acetylated batch would not replicate the published biological activity profile. Documentation is accessible through the batch-specific COA library.
The three compounds cover the immune research space from three non-overlapping mechanisms. Tα1 (TLR2/TLR9, DC maturation, adaptive immune calibration) is the upstream adaptive immune modulator — the compound with the broadest clinical validation (35+ countries, 11,000+ subjects) and the strongest antiviral/anticancer evidence. LL-37 (TLR4/LPS neutralization, membrane disruption) is the innate antimicrobial compound for wound healing and endotoxin research. KPV (NF-κB inhibition, PepT1/IBD delivery) is the targeted intestinal anti-inflammatory. A catalog offering all three positions as a comprehensive immune research platform covering adaptive immunity, innate antimicrobial defense, and mucosal inflammation — the full spectrum of immune biology research from a single buyer audience, with no content overlap between the three guides.
Key Takeaways
Research Takeaways
- Deepest human RCT evidence base in YPB catalog: 30+ RCTs, 11,000+ subjects, no dose-limiting toxicities. HBeAg seroconversion RR 2.31 (95% CI 1.52–3.51) in hepatitis B meta-analysis.
- TLR2/TLR9 dual mechanism: mDC Th1 activation (NF-κB/p38) + pDC IFN-α/IFN-γ induction (IRF3/IRF7) + IDO/Treg tolerance calibration — bidirectional immunomodulation, not simple stimulation.
- 35+ country approvals (hepatitis B/C; Italy melanoma): The most internationally validated research peptide in the YPB catalog.
- FDA non-approval reflects commercial not scientific barriers — non-patentable sequence removes incentive for US registration trial; scientific evidence widely considered sufficient by international regulators.
- N-terminal acetylation required: Ac- form (3,108 Da) has full activity; non-acetylated (3,066 Da) has reduced activity. 42 Da difference confirmed by MS in COA.
- Derived from prothymosin alpha (113 AA precursor) by post-translational acetylation and cleavage — endogenous thymic peptide with conserved sequence across mammalian species.
Business Takeaways
- $120 MSRP — contact YPB for confirmed wholesale pricing at Premier tier.
- ~6,600 monthly searches at low-medium KD — immune, oncology, and longevity research audiences combined.
- Strongest clinical evidence narrative in the immune category — 35-country approval + 11,000 subjects + pooled RCT data creates content that significantly outperforms generic “immune peptide” descriptions.
- Tα1 + LL-37 + KPV immune trio covers adaptive immunity, innate antimicrobial, and mucosal anti-inflammation from a single immune research buyer audience at three separate price points.
Ready to add Thymosin Alpha-1 to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”thymosin-alpha-1″]